[Clinical experiences in the treatment of endometriosis with the LH-RH analog buserelin with special reference to the post-therapy course].

The current therapy study with 50 patients showed that a reversible down regulation of the ovaries is possible. Particularly in cases with severe endometriosis a rapid release of pain can usually be achieved. Further development of the disease could be prevented and in two third of the cases even a partial reduction of tumor size.

[Initial results in the treatment of endometriosis with the LH-RH analog buserelin].

Twenty-six women, most of them with advanced endometriosis (Stage III according to Acosta), were treated for six months with the LH-RH agonist Buserelin. After initially increased liberation both of the gonadotropins as well as of the sexual steroids there was consecutive inhibition of gonadal function, especially after inhibition of FSH secretion. Within two to four weeks estradiol production was completely and lastingly suppressed in 21 of the 26 women.

Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients.

double-blind cross-over study with Org OD 14 was done in 35 post-menopausal patients aged 48-69 years who had hot flushes and other associated symptoms. Patients were randomly allocated to Org OD 14 or to placebo as first treatment. Each period of treatment lasted for 6 weeks and there were no intervals between treatments.

[The influence of long-term medication with the LH-RH analogue buserelin on the regulation of the menstrual cycle (author's transl)].

We investigated in 70 women over a period of 6 months the influence of different dose regimen of the potent LH-RH analogue Buserelin (HOE 766: 400, 200, 100 micrograms per day) on pituitary and ovarian function. The histological findings of the endometrial biopsy specimen (n = 109) were correlated with the hormonal profiles and the bleeding pattern. There was an evident dose-related inhibition of ovulation or corpus luteum integrity.

Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?

The long-acting stimulatory luteinizing hormone - releasing hormone analogue D-Ser(TBU)6-EA10-LH-RH (buserelin) was administered intranasally once daily in a dose of 400 mcg to 24 normally ovulating women and to 4 women with pre-existing endocrine dysregulation. Ovulation was inhibited in 136 out of 156 treatment months. In 20 treatment months, progesterone values temporarily increased indicating luteinization of follicles or ovulation with defective corpus luteum function.

Detection of ovulation by a radioreceptor assay for human luteinizing hormone.

A specific, sensitive, and rapid radioreceptor assay (RRA), employing membranes from bovine testes as receptor and [125I]hLH as radioligand, has been developed for measurement of human LH in serum. This RRA was used to determine the time of ovulation in seven women. For comparison, four hourly values around midcycle were measured by RIA.

[First results with a new prostaglandin E2-derivate (author's transl)].

A new tissue-selective prostaglandin E2-derivate, 16-Phenoxy-prostaglandin E2-methansulfonamide (SH B 286) developed by Pfizer, USA, and Schering, Germany, has been investigated as abortifacient using the intrauterine as well as intravenous route of application. Vital signs, intrauterine pressure, serum levels of steroid hormones, hPL and hCG were recorded before, during and after administration of Pg SH B 286. By using 100--250 microgram Pg SH 286 extraamniotically abortion rates reached 80%.

[Hormonal regulation mechanisms during puerperium].

The regulation of the hypothalamic-hypophyseal-ovarian axis during puerperium is reviewed. The lactotrophic hormone prolactin is necessary for the growth of the milk producing system, initiation and maintenance of lactation. Inappropriate responsiveness of the hypothalamic-hypophyseal-ovarian system causes independent of the actual prolactin serum values postpartum amenorrhea during early puerperium.

[Critical evaluation of clinical and hormonal parameters for the optimal timing of induction of ovulation with gonadotropins (author's transl)].

In 9 hypogonadotrophic, normoprolactinemic women with primary or secondary amenorrhea, who were infertile, 16 treatment cycles with menopausal gonadotropin and chorionic gonadotropin (HMG-HCG) were carried out. Nine treatment cycles were monitored indirectly with the cervical factor and hormonal cytology. The concomitant serum estradiol and progesterone values were later determined by radioimmunoassays.

[The effect of several sexual steroids, 2-bromo-ergokryptin and lisurid-hydrogenmaleate an the postpartum concentration of serum prolactin and lactation (author's transl)].

The effect of Ablacton, Estrovis 4000, 2 Brom-alpha-ergokryptin (Cb 154) and of Lisurid-hydrogenmaleate (LHM) on lactation and the serum concentration of prolactin postpartum was studied. 10 normal nursing postpartum patients served as control. LHM was tested in a double blind study compared to placebo.